iwNHL 2015 roundtable: Day 2 highlights – lenalidomide and ibrutinib for DLBCL

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They discuss a phase 1b/2 clinical trial that was designed to assess the safety and efficacy of ibrutinib and lenalidomide in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Share this video  
3rd October 2015